Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards

Core Insights - Incannex Healthcare Inc. has received the Research and Development Award in the Respiratory Disorders category at the 2025 Clinical Trials Arena Excellence Awards for its innovative work on IHL-42X, an oral fixed-dose combination therapy for obstructive sleep apnea (OSA) [1][2] Company Overview - Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on developing combination therapies targeting chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder [9][10] - The company's lead product candidate, IHL-42X, is a combination of dronabinol and acetazolamide aimed at treating adults with moderate-to-severe OSA [3][9] Product Development - IHL-42X is designed as a non-invasive pharmacologic alternative for patients who struggle with device-based therapies, addressing the significant unmet medical need in OSA management [3][6] - The development strategy for IHL-42X is supported by a robust Phase 2 clinical program that includes objective polysomnography outcomes and validated patient-reported measures [4][5] Recognition and Impact - The Clinical Trials Arena Excellence Awards recognize companies that drive positive change in the industry, highlighting Incannex's research-driven approach to addressing unmet needs in respiratory medicine [2][5] - The award reflects the company's commitment to evidence-based innovation and its broader pipeline strategy focused on combination medicines [5][6]